Skip to main content

Advertisement

SpringerLink
Log in

Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background and purpose

Many studies have been done to determine the distribution of acetylator phenotypes among populations of different geographic origin. The goal of this study was to investigate the acetylator phenotypes of the Iranian population and compare them between tubercular patients and healthy subjects.

Methods

The study population consisted of two groups; the first group included 100 newly diagnosed tubercular patients and the second group consisted of 100 healthy subjects. Acetylator phenotype was determined from the metabolic ratio of acetyl-isoniazid to isoniazid in the plasma samples. Metabolic ratio was used to classify subjects as slow (≤0.70) or fast acetylators (>0.70).

Results

In the tubercular patients, the frequencies of slow and fast acetylator phenotypes were 62 and 38%, respectively. Of the healthy individuals, 45% were found to be slow acetylators and the remaining 55% were fast acetylators.

Conclusion

It seems that tubercular patients metabolize isoniazid more slowly than healthy individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR (2005) INH pharmacokinetic in children treated for respiratory tuberculosis. Arch Dis Child 90:614–618

    Article  CAS  PubMed  Google Scholar 

  2. Weber WW, Hein DW (1979) Clinical pharmacokinetics of INH. Clin Pharmacokinet 4:401–422

    Article  CAS  PubMed  Google Scholar 

  3. The American Pharmacists Association (APhA) (2006) Drug information handbook international, 14th edn. Lexi-Comp, The American Pharmacists Association (APhA), Hudson, OH, pp 936–938

    Google Scholar 

  4. Meyer UA, Zanger UM, Skoda RC, Grant D, Blum M (1990) Genetic polymorphism of drug metabolism. Progress in liver diseases. Prog Liver Dis 9:307–323

    CAS  PubMed  Google Scholar 

  5. Evans DA, Manley KA, McKusick VA (1960) Genetic control of INH metabolism in man. Br Med J 2:485–491

    Article  CAS  PubMed  Google Scholar 

  6. Schoeman JF, Morkel A, Seifart HI, Parkin DP, Van Helden PD, Hewlett RH, Donald PR (1998) Massive posterior fossa tuberculous abscess developing in a young child treated for miliary tuberculosis. Possible role of very rapid acetylation of INH. Pediatr Neurosurg 29:64–68

    Article  CAS  PubMed  Google Scholar 

  7. The American Society of Health-System Pharmacists (AHFS). Drug Information 2007:554–559

  8. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RL, Gregianini TS, Hutz MH, Rossetti ML, Zaha A (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64:673–678

    Article  CAS  PubMed  Google Scholar 

  9. Steichen O, Martinez-Almoyna L, De Broucker T (2006) Isoniazid induced neuropathy: consider prevention. Rev Mal Respir 23:157–160

    CAS  PubMed  Google Scholar 

  10. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269–296

    Article  CAS  PubMed  Google Scholar 

  11. Sunahara S, Uren M, Agawa M (1961) Genetic and geographical studies on INH inactivation. Science 134:1530–1531

    Article  CAS  PubMed  Google Scholar 

  12. Seifart HI, Parkin DP, Botha FJ, Donald PR, Van Der Walt BJ (2001) Population screening for INH acetylator phenotype. Pharmacoepidemiol Drug Saf 10:127–134

    Article  CAS  PubMed  Google Scholar 

  13. World Health Organization Global Tuberculosis Programme (2003) Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.13, 3rd edn. WHO, Geneva

    Google Scholar 

  14. Wilcke JT, Døssing M, Angelo HR, Askgaard D, Rønn A, Christensen HR (2004) Unchanged acetylation of INH by alcohol intake. Int J Tuberc Lung Dis 8:1373–1376

    CAS  PubMed  Google Scholar 

  15. Fox HH, Gibas JT (1953) Synthetic tuberculostat. Acyl derivatives of isonicotinyl hydrazine. J Org Chem 18:1375–1379

    Article  CAS  Google Scholar 

  16. Fox HH, Gibas JT (1953) Synthetic tuberculostat. Alkidenyl derivatives of isonicotinyl hydrazine. J Org Chem 18:983–989

    Article  CAS  Google Scholar 

  17. Fox HH, Gibas T (1953) Synthetic tuberculostat. Mono-alkyl derivatives of isonicotinyl hydrazine. J Org Chem 18:994–1002

    Article  CAS  Google Scholar 

  18. Hutchings A, Monie RD, Spragg B, Routledge PA (1983) High performance liquid chromatographic analysis of INH and acetylINH in biological fluids. J Chromatogr 277:385–390

    Article  CAS  PubMed  Google Scholar 

  19. Hutchings A, Routledge PA (1986) A simple method for determining acetylator phenotype using INH. Br J Clin Pharmacol 22:343–345

    CAS  PubMed  Google Scholar 

  20. Miscoria G, Leneveu A, Walle C, Roux A (1988) Application of a method of analysis using high performance liquid chromatography of INH and acetylINH to determine the phenotype of acetylation. Ann Biol Clin 46:734–740

    CAS  Google Scholar 

  21. Kohno H, Kubo H, Takada A, Mori M, Arias TD (1996) INH acetylation phenotyping in the Japanese: the molar metabolic ratio INH/AcINH. Am J Ther 3:74–78

    Article  PubMed  Google Scholar 

  22. Gupta RC, Nair CR, Jindal SK, Malik SK (1984) Incidence of INH acetylation phenotype in North Indians. Int J Clin Pharmacol Ther Toxicol 22:259–264

    CAS  PubMed  Google Scholar 

  23. Matar KM, Mayet AY, Ayoola EA, Bawazir SA, Al-Faleh FZ, Al-Wazzan A (2004) INH acetylation in Saudi Arabs. J Clin Pharm Ther 29:443–447

    Article  CAS  PubMed  Google Scholar 

  24. Irshaid YM, Al-Hadidi HF, Abuirjeie MA, Rawashdeh NM (1991) N-acetylation phenotyping using dapsone in a Jordanian population. Br J Clin Pharmacol 32:289–293

    CAS  PubMed  Google Scholar 

  25. Sohrani AS, Ahmad B, Janbaz KH (1995) Acetylation percentage method for determination of acetylator status in human volunteers and tuberculosis patients. Pak J Pharma Sci 8:11–16

    CAS  Google Scholar 

  26. Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, Iwakawa S, Okumura K (2001) N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 24:544–549

    Article  CAS  PubMed  Google Scholar 

  27. Hassanzadeh MK, Khashayarmanesh Z (1999) N-acetylation phenotyping using INH in an Iranian and an Afghani population. Indian J Pharm Sci 61:297–300

    CAS  Google Scholar 

  28. Bakayev VV, Mohamadi F, Javeri A, Masjedi MR, Velayati AA (2004) Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol 60:467–471

    Article  CAS  PubMed  Google Scholar 

  29. O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10:171–182

    Article  PubMed  Google Scholar 

  30. Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A (2009) Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diagn Ther 13:49–58

    CAS  PubMed  Google Scholar 

  31. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M, Milami I (2007) Genotyping and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol 34:1207–1211

    CAS  PubMed  Google Scholar 

  32. Küpeli E, Karnak D, Beder S, Kayacan O, Tutkak H (2008) Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. Respiration 75:73–78

    Article  PubMed  Google Scholar 

  33. Drobitch RK, Tomilo M, Svensson CK (1992) Immunomodulation and drug acetylation: influence of the immunomodulator tilorone on hepatic, renal and blood N-acetyltransferase activity and on hepatic cytosolic acetyl coenzyme A content. Biochem Pharmacol 43:1643–1648

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This study was supported by Pharmaceutical Sciences Research Center of Tehran University of Medical Sciences and there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pharmacotherapy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Hossein Khalili, Simin Dashti-Khavidaki & Reza Mahjub

  2. Department of Medical Chemistry, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Mohsen Amini

  3. Department of Infectious Disease, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Mahboobeh Hajiabdolbaghi

  4. School of Pharmacy, Tehran University of Medical Sciences, P.O. Box: 14155/6451, Tehran, Postal Code: 1417614411, Iran

    Hossein Khalili

Authors
  1. Hossein Khalili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simin Dashti-Khavidaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohsen Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reza Mahjub
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahboobeh Hajiabdolbaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hossein Khalili.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khalili, H., Dashti-Khavidaki, S., Amini, M. et al. Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?. Eur J Clin Pharmacol 66, 261–267 (2010). https://doi.org/10.1007/s00228-009-0745-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0745-1

Keywords

Search

Navigation